RU EN

The state contract 02.435.11.1008

 
 
 validation   about   publications     

 
 

The validation of SOL docking program

 

 
 
Description
First validation
Second validation
References
 
 
 

References

1. Word, J.M.; Lovell, S.C.; Richardson. J.S.; Richardson, D.C. Asparagine and glutamine: using hydrogen atom contacts in the choice of sidechain amide orientation. J. Mol. Biol. 1999, 285, 1733-1745.
2. Halgren, T.A. Merck Molecular Force Field. I. Basis, form, scope, parametrization and performance of MMFF94. Journal of Computational Chemistry 1996, 5&6, 490-519.
3.Halgren, T.A. Merck Molecular Force Field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. Journal of Computational Chemistry 1996, 5&6, 520-552.
4. Halgren, T.A. Merck Molecular Force Field. III. Molecular geometries and vibrational frequencies for MMFF94. Journal of Computational Chemistry 1996, 5&6, 553-586.
5. Halgren, T.A.; Nachbar, R.B. Merck Molecular Force Field. IV. Conformational energies and geometries for MMFF94. Journal of Computational Chemistry 1996, 5&6, 587-615.
6. Halgren, T.A. Merck Molecular Force Field. V. Extension of MMFF94 using experimenatal data, additional computational data and empirical rules. Journal of Computational Chemistry 1996, 5&6, 616-641.
7. Grigoriev, F.V.; Romanov, A.N.; Kondakova, O.A.; Luschekina, S.V.; Sulimov, V.B. The algorithm of the force parameters placing at the atoms of organic molecules and proteins in the frame of the force field MMFF 94. Numerical Methods and Programming 2006, 7, 128-136 (in Russian).
8. NCI (National cancer institute) diversity data base
 http://dtp.nci.nih.gov/docs/3d_database/Structural_information/structural_data.html
9. Stahl, M.; Rarey, M. Detailed Analysis of Scoring Functions for Virtual Screening. J. Med. Chem. 2001, 44, 1035-1042.
10. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3Datomic coordinates for organic molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
11. Maruyama, I. Jpn J. Clin. Hematol. 1990, 31, 776-781.
12. Kikumoto, R.; Tamao, Y.; Tezuka, T.; Tonomura, A.; Hara, H.; Ninomiya, K.; Hijikata, A.; Okamoto, S.Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl]-2-piperidinecarboxylic acid. Biochemistry 1984, 23, 85-90.
13. Okamoto, S.; Hijikata, A. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochemical and Biophysical research communications 1981, 101, 440-446.
14. Linder, R.; Frebelius, S.; Jansson, K.; Swedwnborg, J. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood Coagulation and Fibrinolysis 2003, 14, 139-146.
15.Okamoto, S.; Hijikata-Okunomiya, A. Synthetic selective inhibitors of thrombin. Methods in Enzymology 1993, 222, 328-340.
16. Hijikata-Okunomiya, A.; Okamoto, S. A strategy for a rational approach to designing synthetic selective inhibitors. Seminars in Thrombosis and Hemostasis 1992, 18, 135-140.
17. Vacca, J. New advances in the discovery of thrombin and factor Xa inhibitors. Current Opinion in Chemical Biology 2000, 4, 394-400.
18. Steinmetzer, T.; Hauptmann, J.; Sturzebecher, J. Advances in the development of thrombin inhibitors. Exp. Opin. Invest. Drugs. 2001, 10, 845-864.
19. Shafer, J.A.Cardiovascular chemotherapy: anticoagulants. Current Opinion in Chemical Biology 1998, 2, 458-465.
20. Hauptmann, J.; Sturzebecher, J. Synthetic inhibitors of thrombin and Factor Xa: from bench to bedside. Thrombosis Research 1999, 93, 203-241.
21. Shikha Varma. 3d US Catalyst User’s Group meeting Boehringer-Ingelheim pharmaceuticals, Inc. May 11, 2001
22. Pauls, H.W.; Ewing, W.R.; Choi-Sledeski, Y.M.The design of competitive, small-molecule inhibitors of coagulation Factor Xa.Frontiers Med. Chem. 2004, 1, 129-152.
23. V.Sulimov, A.Romanov, F.Grigoriev, O.Kondakova, A.Sulimov, P.Bryzgalov, S.Zhabin, A.Chernobrovkin, S.Sobolev “Web-oriented system Keenbase for virtual screening and design of new ligands for biological macromolecules. Application for new drug searches”, Saint-Petersburg International Workshop on NanoBiotechnologies,
27 -29 November 2006 Saint-Petersburg Russia, Abstracts, pp.33-34.
24. V.B.Sulimov, A.N.Romanov, O.A.Kondakova, E.I.Sinauridze, A.A.Butylin, I.V.Gribkova, A.S.Gorbatenko, A.A.Bogoliubov, I.Yu.Titov, E.V.Polunin, Yu.V.Kuznetsov, I.V.Taidakov, V.V.Voevodin, S.I.Sobolev, F.I.Ataullakhanov "New Thrombin Inhibitors: Molecular Design and Experimental Discovery", BIT's 5th Anniversary Congress of International Drug Discoveru Science & Technology (IDDST), Serial II: Advances and Challenges Toward Major Diseases. Theme: Extension on New Hope, November 7-13, 2007, Xi'an & Beijing, China, p.145.
25. Virtual screening in drug discovery. Alvarez J., Shoichet B.(Ed.)Taylor & Francis, 2005.
26. http://www.ccdc.cam.ac.uk/products/life_sciences/validate
27. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissing, H.; Shindyalov, I.N.; Bourne, P.E.  The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.


  

 

 

 

 


© 2006, SRCC MSU